Analysis of antibody production in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.

Recruiting

• Conditions: rheumatic diseases; rheumatoid arthritis; 10003816; 10023213

• Registration Number: NL-OMON42179
• Lead Sponsor: Jan van Breemen Instituut

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

Patients with:
- rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis
- who are prescribed adalimumab, etanercept, golimumab, certolizumab pegol or abatacept by their rheumatologist
- who gave written informed consent for the study

Exclusion Criteria

None.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Plasma: autoantibody and anti-drug antibody characteristics, drug level,<br /><br>other antibody responses related to treatment and disease, factors associated<br /><br>with inflammation (e.g. TNF).<br /><br>- Peripheral blood mononuclear cells (PBMCs): cell characteristics.<br /><br>- PBMC culture supernatant: Antibody production, cytokine production,<br /><br>production of factors associated with inflammation.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>